Fri Sep 20 07:17:04 UTC 2024: ## Cue Biopharma Sees Short Interest Drop Amidst Mixed Analyst Opinions
**[City, State] -** Cue Biopharma, Inc. (NASDAQ:CUE) saw a notable decrease in short interest during August, falling 6.3% to 3,430,000 shares, according to MarketBeat News. This comes amidst a mixed bag of analyst opinions, with some lowering their price targets while others maintain optimistic outlooks.
The short-interest ratio currently stands at 7.7 days, based on an average daily trading volume of 446,900 shares. This suggests a potential decrease in investor skepticism towards the company’s future prospects.
JMP Securities, Stifel Nicolaus, and Piper Sandler all recently revised their price targets for Cue Biopharma. While JMP Securities downgraded their target to $2.00 and Stifel Nicolaus lowered it to $4.00, all three maintain a positive outlook on the stock, with JMP issuing a “market outperform” rating and the other two issuing “buy” and “overweight” ratings respectively.
Despite the differing price targets, the overall consensus among analysts remains positive, with a “Buy” rating and an average target price of $5.00, according to MarketBeat.
Cue Biopharma’s stock opened at $0.57 on Friday, with a 50-day moving average of $0.71 and a 200-day moving average of $1.32. The company reported strong earnings in August, beating analyst estimates for both revenue and earnings per share.
Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat diseases by selectively engaging and modulating T cells within the patient’s body. Their lead product, CUE-101, is currently being investigated for the treatment of HPV16+ driven recurrent/metastatic head and neck cancer.
While the recent short-interest decrease and mixed analyst opinions paint a complex picture for Cue Biopharma, investors will be keenly watching the company’s progress in clinical trials and its future financial performance to gauge the long-term viability of this promising biotech firm.
First Piper 